Wall Street Set to Open Higher
9:16AM ET 6/17/2022 MT NewswiresUS stocks look set to open Friday trading higher as Federal Reserve Chairman Jerome Powell speaks before the inaugural Conference on the International...
Quotes Snapshot > ATHX
Athersys Inc ATHX:NASDAQ
Last Price$0.25Cboe Real-Time Last Sale as of 2:57PM ET 7/01/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.01(3.77%)
Bid (Size)$0.25 (200)
Ask (Size)$0.25 (200)
Day Low / High$0.25 - 0.27
Volume1.6 M
Read more news Recent News
US Futures Move Higher Friday
8:16AM ET 6/17/2022 MT NewswiresUS stock futures are moving higher during Friday's premarket session ahead of remarks to be given by Federal Reserve Chairman Jerome Powell before the...
Top Premarket Gainers
7:51AM ET 6/17/2022 MT NewswiresRevlon (REV) shares surged 86%, rebounding from Thursday's volatile session following the company's announcement of filing for Chapter 11 bankruptcy...
Athersys Reducing Workforce by 70% to Cut Costs -- Shares Fall 7% After-Hours
5:40PM ET 6/02/2022 MT NewswiresAthersys (ATHX) said Thursday it is cutting its workforce by up to 70% as part of its restructuring plan to lower costs and focus on existing clinical...
View all Commentary and Analysis
Athersys (ATHX) Investor Presentation Treasure Data - Slideshow
1:31PM ET 5/26/2022 Seeking AlphaAthersys: Focus On Stroke
9:40AM ET 5/04/2022 Seeking AlphaAthersys - Hero Or Zero Opportunity
10:56AM ET 4/18/2022 Seeking AlphaAthersys, Inc. (ATHX) CEO Daniel Camardo on Q4 2021 Results - Earnings Call Transcript
8:47PM ET 3/15/2022 Seeking AlphaCompany Profile
Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 07/01/2022 DEFA14A |
| Chief Executive Officer & Director | Daniel A. Camardo |
| Chief Operating Officer | Maia A. Hansen |
| Head-Information Technology & Communications | Rakesh Ramachandran |
| Senior Director-Medical & Head-Clinical Operations | Eric Jenkins |
Company Highlights
| Price Open | $0.26 |
| Previous Close | $0.26 |
| 52 Week Range | $0.18 - 1.81 |
| Market Capitalization | $63.0 M |
| Shares Outstanding | 252.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.35 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -981.52% |
| Return on Equity | -429.24% |
Analyst Ratings as of 06/02/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |